Indeed, patients bearing alterations in MSH6 or PMS2 benefit more from current colonoscopy surveillance programs than MLH1 or MSH2 mutation carriers due to the different type of tumorigenesis involved [60] and have been reported to have a lower risk of developing CRC along with a later age at presentation [61]. The gene discussed is MSH2; the disease is colorectal carcinoma.